Windlas Biotech meets FY26 estimates; dividend raised to ₹6.30
Revenue grew 19% to ₹9,041 mn, net profit rose 9% to ₹664 mn. Results were widely anticipated with no material surprises.
— 3 earlier stories on Windlas Biotech Ltd. → 9% Net profit growth to ₹664 mn
What's new
- FY26 revenue up 19% YoY to ₹9,041 mn
- Net profit rose 9% YoY to ₹664 mn
- Dividend hiked from ₹5 to ₹6.30 per share
Why it matters
Steady operational performance but fully expected after prior guidance and buyback completion. No new tradeable insights for the micro-cap pharma stock.
What we're watching
- Any change in growth trajectory in FY27
- Sustainability of margin trends
The full read
Windlas Biotech's audited FY26 results confirm the trajectory already implied by its buyback and prior commentary. Revenue hit ₹9,041 million, up 19%, and net profit rose 9% to ₹664 million. The dividend increase to ₹6.30 per share (126% face value) is modest but welcome. The numbers are clean but routine — no surprises, no guidance deviation. For a micro-cap pharma that has already communicated its outlook, this annual filing offers nothing to alter the consensus view.
Mentioned: ₹9,041 mn revenue · ₹664 mn profit · ₹6.30 dividend
Primary source BSE filings for WINDLAS NSE filings for WINDLAS Research WINDLAS on Tijori Finance Our reading is derived from the exchange filing. Verify on the exchange before acting.